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Objectives: To compare the methodological and reporting quality of updated 
systematic reviews (SRs) and original SRs. 
Study Design and Setting: We included 30 pairs of non-Cochrane updated and 
original SRs, identified from a search of PubMed and Embase.com. We used 
AMSTAR 2 to assess methodological quality and PRISMA for reporting quality. 
Stratified analyses were conducted to compare the differences between updated SRs 
and original SRs and explore factors that might affect the degree of quality change. 
Results: Of the 60 non-Cochrane SRs, only 2 (3.3%) were of low quality, the 
remaining 58 (96.7%) were of critical low quality. There were no statistically 
significant differences in methodological quality between the updated SRs and 
original SRs, although the compliance rates of 8 items of updated SRs were higher 
than that of original SRs. Updated SRs showed an improvement on 15 PRISMA items, 
but no items with statistically significant differences. The differences in fully reported 
AMSTAR 2 and PRISMA items between original SRs and up ated SRs were also not 
statistically significant after adjusting for multiple review characteristics. 
Conclusions: The methodological and reporting quality of update SRs were not 
improved compared with original SRs, although the quality could be further improved 
for both updated SRs and original SRs. 
 
Keywords: Systematic reviews; Updating; AMSTAR 2; PRISMA; Methodological 
quality; Reporting quality 
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Running title：Methodological and reporting quality of original and updated SRs 
 
What is new?  
 
Key findings  
 The methodological and reporting quality of non-Cochrane updated SRs were not 
improved compared with the original SRs.  
What this adds to what was known?  
 This study investigated the methodological and reporting quality of the 
non-Cochrane updated SRs and original SRs in both overall fully reported items 
and individual item of AMSTAR 2 and PRISMA checklists and assessed certain 
factors that may affect the extent of the methodological and reporting quality 
changes during the update process. 
What is the implication and what should change now? 
 The identified deficiencies should be paid more attention, especially for the 
updated SRs. Researchers, journal editors, and peer revi wers should ensure that 
the methodological and reporting guidelines are strictly followed before 
publication. Further research should focus on developing a methodological or a 





Systematic reviews (SRs) are fundamental tools for generating reliable medical 
information [1, 2], which provides a comprehensive synthesis of a large amount of 
evidence to help clinicians keep up with the pace of medical literature, explains the 
differences between studies on the same issue, formulates clinical policies, combines 
best evidence with clinical practice, and suggests directions for new research [3-6]. 
Recent estimates suggest that more than 8,000 new SRs were published in Medline 
annually, which is equivalent to a threefold increas  over the past decade [7, 8]. 
However, SRs are most useful when they are kept up to date [9-11]. Therefore, as SRs 
continue to increase, more and more SRs are updated to include new evidence, which 
can relatively reduce publication bias and increase the credibility of the results of SRs 
[10, 12, 13]. However, empirical studies have shown that there are a large number of 
unnecessary, misleading, and conflicting SRs and meta-analyses, in part because of 
inappropriate methodological design, conduct, or repo ting [14, 15]. SRs of 
incomplete reports or flawed implementation methods can lead to biased 
recommendations and may distort decisions [16, 17],limiting the role of SR in 
decision-makers [18]. 
The methodological quality and reporting quality are considered as the two main 
aspects of the quality of an SR, which aims to assess, and hopefully improve, the 
design, conduct, and reporting of SRs [19]. For example, the Assessment of Multiple 
Systematic Reviews 2 (AMSTAR 2) tool is aimed to improve the methodological 
quality of SRs as well as the Preferred Reporting Items of Systematic reviews and 
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Meta-Analyses (PRISMA) statement focused on the advance of reporting quality [20, 
21]. Previous studies have evaluated the quality of SRs in different fields using 
AMSTAR and PRISMA tools and they all showed that SRs have some weaknesses 
and the quality needs to be further improved [2, 8, 15, 22-24]. Besides, the study also 
has compared the quality of updated and original Cochrane SRs [25], which to some 
extent were considered to have better methodological rigor and more frequent updates 
than peer-reviewed paper journals [23, 26]. But there was still a lack of empirical 
evidence to evaluate the impact of updating on the quality of non-Cochrane reviews, 
and whether certain factors affect the improvement of quality during the update 
process has not been evaluated nor studied. 
This study is a sister paper of our project, another paper will explore whether the 
updated SRs exhibit outcomes change and whether the updated SRs improve the 
precision of outcomes. The primary objective of thepr sent study was to assess 
methodological and reporting quality of included SRs. The secondary objective was to 
compare the differences between the updated SRs and original SRs in the quality. The 
third objective was to determine whether certain characteristics (e.g., updated team, 





2.1. Criteria for considering reviews for inclusion 
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Systematic reviews of interventions with or without meta-analysis that met the 
following criteria were included: (1) was a review article and explicitly described 
methods of study selection, and explicitly reported the methods of evidence synthesis 
[22]; (2) original SRs and updated SRs of randomized controlled trials (RCTs) or 
quasi-randomized controlled trials that evaluated clinical effects of health care 
interventions; and (3) all the original SRs and update  SRs were published in English 
language. 
Studies including the following were excluded: (1) SRs that included RCTs and 
nonrandomized studies or only included nonrandomized studies; (2) SRs did not focus 
on health care interventions such as etiology, diagnosis, and prognosis; (3) SRs did 
not clearly state "update" in the titles or articles; (4) the original SR or updated SR is a 
Cochrane review; (5) the second analysis of previous SR; (6) overviews of SRs, 
methodological reviews, umbrella overviews, scoping or rapid reviews, review 
protocols, abstracts, conference proceedings, and letters to editors. 
 
2.2. Electronic searches 
 
We searched the PubMed and Embase.com using the phrases “systematic 
review”, “meta-analysis”, “indirect comparison”, “indirect treatment”, “mixed 
treatment comparison”, “multiple treatment comparison”, and “update” to identify 
updated SRs, across all years up to March 3, 2019. We did not apply any date 
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restriction. The search strategy of Embase is present d in Appendix Word 1. 
 
2.3. Selection of reviews 
 
We imported the retrieved records into EndNote X8 (Thomson Reuters 
(Scientific) LLC Philadelphia, PA, US) for management. Two overview authors (Y.G. 
and Y.T.C.) independently screened the results of the electronic search by title and 
abstract. The full-text versions of the possibly relevant reviews were obtained for 
further assessment to determine the final inclusion according to the eligibility criteria. 
If a system review had multiple updated versions, we would include the latest one. We 
resolved disagreements through discussions with a third reviewer (J.H.Z, or J.H.T.). 
 
2.4. Data collection 
 
One reviewer (Y.G., Y.T.C., K.L.Y., or M.L.) extracted data from the included 
SRs using a pre-defined data extraction form and a second reviewer checked the 
extracted data for accuracy and completeness. We resolved any discrepancies by 
consensus. A third reviewer (J.H.Z, or J.H.T.) was requested for discussion if the 
agreement could not be reached. The data extraction form included the following 
details: first author, journal name, publication year, country of authors, whether SRs 
involved co-first author, whether SRs had co-correspondence author, whether 
statistician, epidemiologist, or methodologist (based on the author’s current academic 
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position) was involved, whether SRs had a priori protocol, the number of RCTs 
included, funding source (nonprofit, for-profit, unf ded, or not reported), topic of 
interest, methodological quality, and reporting quality. 
 
2.5. Assessment of methodological and reporting quality 
 
The methodological quality of the included SRs was evaluated according to the 
Assessment of Multiple Systematic Reviews 2 (AMSTAR 2) tool, which is a revised 
version of the original AMSTAR instrument, allowing for the evaluation of SRs based 
on random and non-randomized studies [27, 28]. The AMSTAR 2 contains 16 items, 
among which seven are critical domains. The overall confidence of the results of the 
review was rated into four levels: high, moderate, low, and critically low [27]. Each 
item was judged as “Yes” (item fully addressed), “No” (item not addressed), or 
“Partial Yes”(item not fully addressed). 
The reporting quality was assessed using the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) statement, which a checklist of 27 
items aimed to improve the completeness and transparency of reporting of SRs [8, 29]. 
We responded each item to “Yes’’ (total compliance), “Partial’’ (partial compliance), 
‘‘No’’ (noncompliance), or ‘‘Can not answer’’ (limited information) [22, 30]. The 
quality of SRs was assessed by one reviewer (Y.G., .T.C., K.L.Y., S.Z.S, J.C., or Y.S.) 
and verified by another. Disagreements were resolved by consensus or third-party 
adjudication if consensus cannot be reached (J.H.Z, or J.H.T.). 
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2.6. Data management and synthesis 
 
We compared the general characteristics between updated SRs and original SRs. 
Frequency and percentage were used for categorical variables, and median and 
interquartile range were used for continuous variables. Chi-squared test or Fisher 
exact test (if a contingency table contained a cell with five or fewer events) was used 
to evaluate the differences in categorical data and two-sample Wilcoxon rank-sum test 
or Student t-test was used to assess the differences i  continuous data [8, 22]. The 
analyses were conducted in IBM SPSS Statistics v. 24.0 (Armonk, NY: IBM Corp.), 
and the statistical level of significance was set at P < 0.05. 
The compliance rate of each item for the methodological and reporting quality 
was calculated with the number acquired “Yes” and the total number of included 
original SRs or updated SRs. Then, we performed a Chi-squared test and calculated 
the odds ratio (OR) with 95% confidence intervals (95% CIs) and P value to compare 
the compliance of each item between updated SRs and original SRs. We created 
bubble plots with Microsoft Excel 2016 (Microsoft Corp, Redmond, WA, 
www.microsoft.com) to present the compliance rate and OR. Considering bubble 
plots according to the compliance rate, the bubble siz represented the number of 
compliance rate, the X-axis represented the AMSTAR 2 or PRISMA items, the Y-axis 
represented the compliance rate of each item. As for bubble plots incorporating OR, 
the bubble size displayed the number of OR, the X-axis represented the AMSTAR 2 
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or PRISMA items, the Y-axis indicated the OR of updated SRs compared to original 
SRs for each item. 
We also computed the number of acquired “Yes” of AMSTAR 2 items and 
PRISMA items for each SR. The mean difference (MD) with 95%CI was calculated to 
compare the mean fully reported items between the original SRs and updated SRs. 
Either bivariate or multiple variable linear regression analysis was used to explore the 
potential factors that affected the fully reported AMSTAR 2 items and PRISMA items 
of original SRs and updated SRs. 
Furthermore, we divided the included SRs into updates by the same team or by 
different teams. In the current study, we defined SR to be updated by the same team if 
the first author or corresponding author did not change by comparing the updated SR 
with the original SR. We categorized SRs with the same interventions or changed 
interventions by comparing the involved interventios of updated SR with the original 
SR. We also identified the updated SRs included the trials that included in the original 
SRs, or did not include the trials included in the original SRs, categorized the updated 
SRs fully included trials of original SRs or partially included trials of original SRs, 
and classified updated and original SRs with a priori protocol or without a priori 
protocol. We then conducted the Chi-squared test and c lculated OR with 95% CIs to 
compare the compliance between updated SRs and original SRs for AMSTAR 2 and 
PRISMA items considering each subgroup, separately. We also calculated the ratio of 
odds ratio (ROR) and P value to compare the extent of the change in compliance of 
each item between SRs to be updated by the same tea and different teams, between 
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SRs with the same interventions and changed interventions, between SRs included the 
trials and did not include the trials included in the original SRs, between SRs fully 
included trials of original SRs and partially included trials of original SRs, and 




3.1. Screening Results 
 
The initial search returned 4997 review records, after titles, abstracts, and 
full-text screening according to the eligible criteria, we included 30 non-Cochrane 
updated SRs and 30 non-Cochrane original SRs. Details of the search screening 
process are presented in Figure 1. The full lists of included SRs can be found in 
Appendix Word 2. 
 
3.2. General characteristics of included SRs 
 
The main characteristics of the included systematic reviews are summarized in 
Table 1. The original SRs were published in 28 different journals and had a median 
journal impact factor of 5.206 (IQR: 2.857 to 17.870). The updated SRs were 
published in 27 different journals and had a median journal impact factor of 3.750 
(IQR: 2.520 to 6.046). The included SRs were published between 1994 and 2018. 
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Compared with original SRs, the updated SRs were more likely to be published in 
journals with lower impact factors and tended to be published between 2011 and 2018. 
Only three SRs with the co-first author, one SR involved co-correspondence author, 
ten SRs had statistical, epidemiological, or methodol gical authors, and there were no 
statistically significant differences between the updated SRs and the original SRs. 
Eight updated SRs and seven original SRs had a priori r tocol. 43.3% of the SRs 
were published by authors from two or more countries, more than half of SRs were 
conducted in Europe, and 25.0% were completed in North America. Only 30.0% of 
the SRs were funded and most of them were funded by the nonprofit sponsor, but 
there were still 61.7% of SRs did not report funding sources. The included SRs 
investigated several interventions in different clini al conditions. Neoplasms (10, 
16.7%), followed by Diseases of the circulatory system (8, 13.3%), were the most 
studied ones, and there were no statistically significant differences in disease 
conditions investigated. 
 
Table 1 The main characteristics of the included SRs 
Characteristics Original SRs Updated SRs P value 
Journal impact factor: median (IQR) 5.206(2.857,17.870) 3.750(2.520,6.046) 0.011  
Year of Publication 
1994 to 2000 3(10.0) 1(3.3) 0.612  
2001 to 2005 8(26.7) 3(10.0) 0.095  
2006 to 2010 9(30.0) 7(23.3) 0.559  
2011 to 2015 10(33.3) 9(30.0) 0.781  
2016 to 2018 0(0.0) 10(33.3) 0.001  
With co-first author (%) 1(3.3) 2(6.7) 1.000  
With co-correspondence author (%) 0(0.0) 1(3.3) 1.000  
With statistician, epidemiologist, or methodologist (%) 7(23.3) 3(10.0) 0.166  
Authors from 2 or more countries (%) 14(46.7) 12(40.0) 0.602  
Origin region (%) 
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Asia 4(13.3) 4(13.3) 1.000  
Europe 16(53.3) 17(56.7) 0.795  
North America 7(23.3) 8(26.7) 0.766  
South America 1(3.3) 0(0.0) 1.000  
Oceania 2(6.7) 1(3.3) 1.000  
Number of RCTs included: median (IQR) 13.5(7.75, 29.25) 18.5(9.75, 30) 0.010  
Funding sources (%) 
Nonprofit sponsor 9(30.0) 7(23.3) 0.559  
For-profit sponsor 1(3.3) 1(3.3) 1.000  
None 2(6.7) 3(10.0) 1.000  
Not reported 18(60.0) 19(63.3) 0.791  
Conditions investigateda (%) 
Neoplasms 5(16.7) 5(16.7) 1.000  
Diseases of the circulatory system 4(13.3) 4(13.3) 1.000  
Diseases of the digestive system 3(10.0) 3(10.0) 1.000  
Diseases of the musculoskeletal system and connective tissue 3(10.0) 3(10.0) 1.000  
Mental and behavior disorders 2(6.7) 2(6.7) 1.000  
Pregnancy, childbirth, and puerperium 1(3.3) 1(3.3) 1.000  
Diseases of the genitourinary system 1(3.3) 1(3.3) 1.000  
Diseases of the infectious disease 1(3.3) 1(3.3) 1.000  
Diseases of the nervous system 1(3.3) 1(3.3) 1.000  
Diseases of the respiratory system 1(3.3) 1(3.3) 1.000  
Endocrine, nutritional, and metabolic disease  1(3.3) 1(3.3) 1.000  
Factors influencing health status and contact with health services 1(3.3) 1(3.3) 1.000  
Any other 6(20.0) 6(20.0) 1.000  
IQR, interquartile range. 
a Conditions were categorized according to the Internatio al Classification of Diseases 11th Revision 
(ICD-11). 
 
3.3. Results of methodological quality 
 
3.3.1. Methodological quality of updated SRs and original SRs 
 
Only two (3.3%) SRs were of low quality, fifty-eight (96.7%) were of critical 
low quality, and none of the SR was of high or moderate quality (Appendix Table 1). 
The difference in the mean fully reported AMSTAR 2 items between updated SRs and 
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original SRs was not statistically significant (MD = 0.03, 95%CI: -1.36 to 1.42, P = 
0.966). Considering individual item, the compliance rates of three items were higher 
than 60.0% for both the updated SRs and original SRs, they were “research questions 
and inclusion criteria include the components of PICO”, “described the included 
studies in adequate detail”, and “used appropriate methods for statistical combination 
of results”. However, all the SRs did not explain their selection of the study designs 
for inclusion in the review, all the original SRs and 96.7% of the updated SRs did not 
report the sources of funding for studies included in the review, no more than 33.0% 
of the SRs provided explicit statement that the review methods were established prior 
to the conduct of the review and clarified the signif cant deviations from the protocol, 
provided a list of excluded studies and justified the exclusions, assessed the potential 
impact of RoB in individual studies on the results of the meta-analysis or other 
evidence syntheses, carried out an adequate investigation of publication bias and 
discussed its likely impact on the results of the review, and reported potential sources 
of conflict of interest (Figure 2, Appendix Table 2). There were no statistically 
significant differences between the updated SRs and the original SRs in the AMSTAR 
2 items, although the compliance rates of 8 items of updated SRs were higher than 
that of original SRs (Figure 3, Appendix Table 2). 
 
3.3.2. Changes in methodological quality of SRs in different groups 
 
Overall, no significant difference was found between SRs with the same team 
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and SRs with different teams (P>0.05), although the SRs updated by different teams 
have a greater degree of quality improvement on 8 items. Compared with SRs with 
different interventions, the SRs with the same intervention had a greater degree of 
quality improvement according to items 2, 8, 12, 14, and 15. However, the differences 
between them were not statistically significant (P>0.05). There were no significant 
differences in the degree of quality improvement betwe n SRs included the trials that 
included in the original SRs and SRs did not include the trials included in the original 
SRs, between SRs fully included trials of original SRs and SRs partially included 
trials of original SRs, and between SRs with a protoc l and SRs without a protocol 
(Appendix Table 3). 
 
3.4. Results of reporting quality 
  
3.4.1. Reporting quality of updated SRs and original SRs 
 
Among the 27 PRISMA items, 6 items obtained a compliance rate higher than 
70.0% for both the updated SRs and original SRs. However, only 26.7% of the 
updated SRs and 23.3% original SRs fully reported th  protocol and registration, 40.0% 
of the SRs presented the data collection process, and less than 32.0% SRs assessed the 
risk of bias across studies in the Methods section. More than 78.0% of the SRs did not 
report the risk of bias across studies in the Results section, and most SRs did not 
clarify the limitations and funding (Figure 4, Appendix Table 4). Compared with the 
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original SRs, the reporting rates of the updated SRs had an improvement on 15 items, 
but no items were observed to have statistically significant differences (Figure 5, 
Appendix Table 4). As for the mean fully reported PRISMA items, no statistically 
significant difference was found between updated SRs and original SRs (MD = 0.10, 
95%CI: -2.37 to 2.57, P = 0.937). 
 
3.4.2. Changes in reporting quality of SRs in different groups 
 
For SRs with different teams, the updated SRs had a low compliance rate in 
reporting of information sources (OR=0.08, 95%CI: 0.01 to 0.76, P=0.014), but there 
were no statistically significant differences in the degree of quality change between 
the SRs with the same team and SRs with different tams for all the 27 items. 
Compared with SRs with the same intervention, those with changed interventions 
often better reported 20 items, although the differences between them were not 
statistically significant. No significant differences were found in the degree of quality 
improvement between SRs included the trials of the original SRs and SRs did not 
include the trials included in the original SRs, between SRs fully included trials of 
original SRs and SRs partially included trials of original SRs, and between SRs with a 
protocol and SRs without a protocol. (Appendix Table 5). 
 
3.5. Results of regression analyses 
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No significant differences were observed in fully reported AMSTAR 2 items of 
original SRs and updated SRs in either bivariate or multiple variable linear regression 
analyses after adjusting for factors of publication year, involved in statistician, 
epidemiologist, or methodologist, impact factor, authors from >1 country, and funding 
support. The fully reported PRISMA items were also not statistically significantly 
associated with original SRs or updated SRs in either bivariate or multiple variable 
linear regression analyses after adjusting for factors with imbalanced distribution 
between SRs (Appendix Table 6). 
 
3.6. Compared with other studies 
 
To compare the methodological quality of the included SRs and SRs in other 
fields, we selected two recently published studies [31, 32] that evaluated the 
methodological quality of SRs using the AMSTAR 2 tool. Compared with study 
conduct by Habtewold et al. [31], the updated SRs and original SRs had significantly 
higher compliances for items “used a comprehensive literature search strategy” and 
“described the included studies in adequate detail”, but had lower compliances for 
items “carried out an adequate investigation of publication bias and discussed its 
likely impact on the results of the review” and “reported any potential sources of 
conflict of interest”. The updated SRs and original SRs had significantly higher 
compliance rates on items 2, 8, and 11 but had significa tly lower compliance rates on 
items 1, 3, 7, 12, 13, 15, and 16 compared with research by Piovani et al [32]. The 
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details of the comparisons were presented in Appendix Table 7. 
Considering the comparisons of reporting quality, we selected two studies [33, 
34], including large samples, that explored the repo ting quality of SRs in the field of 
pain and cancer, respectively. Compared with the study of Riado et al. [33], the 
updated SRs and original SRs had lower compliance i r porting of eligibility criteria, 
study selection, data collection process, data items, study characteristics, limitations, 
and funding. The study of Xu et al. [34] often better reported the objectives, eligibility 
criteria, information sources, data collection process, data items, synthesis of results, 
risk of bias across studies, additional analyses, study characteristics, results of 
individual studies, limitations, and funding. However, all the updated SRs and original 
SRs often better reported the protocol and registration, search, and study selection 




4.1. Summary of findings 
  
This study identified 30 non-Cochrane updated SRs and 30 non-Cochrane 
original SRs published between 1994 and 2018 and assessed the methodological 
quality using AMSTAR 2 tool and reporting quality in terms of the PRISMA checklist. 
Results indicated that the overall methodological quality and reporting quality of 
updated SRs were not improved compared with original SRs, but the compliance rates 
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of many AMSTAR 2 items and PRISMA items were slightly improved with no 
significant difference. The overall fully reported AMSTAR 2 items and PRISMA 
items between original SRs and updated SRs were also not statistically significant 
after adjusting for multiple review factors. 
For overall methodological quality, only two SRs were of low quality and the 
remaining 58 were of critical low quality which indicates that the methodological 
quality needs to be further improved. Considering idividual item of AMSTAR 2, 
only one item obtained compliance higher than 70.0%. Research protocols are an 
important feature of SR, which helps to increase th transparency of the review 
objectives and methods and avoids bias in outcome reporting, and the absence of a 
protocol may result in post-modification of methods [22, 35]. However, only about 
22.0% of SRs provided an explicit statement that the review methods were established 
before the conduct of the review and clarified the significant deviations from the 
protocol. Similar to previous studies [28, 31], our study found that none of the SRs 
explained their selection of the study designs for inclusion in the review and only 
about 21.7% SRs provided a list of excluded studies and justified the exclusions. If 
there is a publication bias, the treatment effect may be overestimated even if the bias 
of risk of the included individual trial is low [36]. But there were still 73.3% of SRs 
did not carry out an adequate investigation of publication bias and discussed its likely 
impact on the results of the review. Furthermore, almost none of the SRs reported the 
sources of funding for the studies included in the review, most SRs did not assess the 
potential impact of risk of bias in individual studies on the results of the meta-analysis 
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or other evidence syntheses and did not report potential sources of conflict of interest. 
There were no statistically significant differences between the updated SRs and the 
original SRs in all AMSTAR 2 items, indicating that the methodological quality of 
updated SRs was not significantly improved. Overall, no significant differences were 
found between SRs with the same team and SRs with different teams, between SRs 
with the same intervention and SRs with changed interventions, between SRs 
included the trials that included in the original SRs and SRs did not include the trials 
included in the original SRs, and between SRs with a protocol and SRs without a 
protocol, which revealed that these factors did not affect the extent to which the 
methodological quality changes during the update process. 
For reporting quality, the compliance rates of six items were higher than 70.0%, 
and only one item was fully reported for the update SRs. The compliance rates of 
updated SRs were better than original SRs in 15 items, but no items were observed to 
have statistically significant differences. However, there were many common defects 
in these SRs, such as “report the protocol and registration”, “present the data 
collection process”, “assess the risk of bias across studies”, and “clarify the 
limitations and funding”. What is more, the reporting flaws were also found in the 
following items: objectives, search, study selection, data items, risk of bias in 
individual studies, and additional analyses. Although the release of the PRISMA 
statement was important to quickly improve the repoting quality of SRs [15], current 
research indicates that this tool does not seem to be well followed. Considering fully 
reported PRISMA items, the difference between original SRs and updated SRs was 
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not statistically significant before and after adjusting for multiple review 
characteristics. For each PRISMA item, there were also no significant differences 
between SRs with the same team and SRs with different teams, between SRs with 
same intervention and SRs with changed interventions, between SRs included the 
trials of the original SRs and SRs did not include trials of the original SRs, and 
between SRs with a protocol and SRs without a protocol. This means whether the 
updates were conducted by the same team, whether the intervention was changed, 
whether the trials of original SRs were included, and whether SRs had a priori 
protocol did not affect the degree of quality improvement during the update process. 
 
4.2. Compared with other studies 
 
To our knowledge, a previous study published in 2006 has evaluated the 
methodological quality using Overview Quality Assesment Questionnaire (OQAQ) 
and reporting quality using Quality of Reporting ofMeta-analyses (QUOROM) 
statement of updated and original versions of the Cochrane SRs [25]. This study 
revealed that there was no overall improvement in the updated SRs in items of 
reporting quality and methodological quality, which is similar to our evaluation using 
AMSTAR 2 and PRISMA checklist. Besides, our research also compared 
methodological and reporting quality of the included updated SRs and original SRs 
with SRs in the other fields. It was found that the m thodological quality of the 
updated SRs and original SRs was similar to SRs in the field of biomedical and public 
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health, as assessed by Habtewold et al [31]. However, th  compliances of eleven 
AMSTAR 2 items of the updated SRs and original SRs were lower than that of the 
study of Piovani et al [32], although only seven items with significant differences. 
This indicated that the methodological quality of bth the updated SRs and original 
SRs was lower than that of the SRs of the inflammatory bowel diseases. But all the 
SRs had the same low compliance rates for ‘‘review contain an explicit statement that 
the review methods were established prior to the conduct of the review”, “explanation 
of the selection of the study designs for inclusion”, and “sources of funding for the 
studies included in the review”. As for reporting quality, the compliance rates of 
sixteen items of the included SRs were lower than the study of Riado et al. [33], and 
the compliance rates of twenty items were lower than Xu et al.'s study [34], revealing 
that the reporting quality of the included SRs was lower than SRs in the field of pain 
and cancer. 
 
4.3. Suggestions for future work 
 
The current study showed that both the non-Cochrane updated SRs and the 
original SRs were of low quality according to the AMSTAR 2 and PRISMA checklists, 
and many items had low compliance rates. The identifi d deficiencies should be paid 
more attention, especially for the updated SRs. Researchers, journal editors, and peer 
reviewers should ensure that the methodological and reporting guidelines are strictly 
followed prior to publication [15]. Our research confirmed that the methodological 
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and reporting quality of the included SRs was lower than SRs in the other fields, so 
the quality of both the original SRs and updated SRs needs to be further improved. A 
lot of important information was not fully reported for updated SRs, and even some 
were not reported. However, many SRs are more focused on new data and analytical 
methods during the update process. But we should know that the scientific quality is 
not only based on data and results, but also on the rigor and appropriateness of 
methods to conduct and report the study. Because decision-makers need to examine 
the evidence before implementing new interventions r diagnostic techniques, the role 
of SRs is increasingly important in healthcare and SRs must provide reliable and valid 
evidence. Thus, it is necessary to develop a methodological quality tool and a 
reporting quality tool that are specifically applicable to the assessment of updated SRs 
or provide a methodological framework for updating SRs. For example, we can 
modify some items of the PRISMA checklist, which defin s that the report should be 
identified as an updated SR in the title, the update  SR should report the reason for 
the update, clarify the studies identified from previous SR, and provide a flow 
diagram including the studies which identified from previous SR. We have conducted 
stratified analyses to explore factors that may affect the degree of quality change 
during the update process. However, all the selected factors did not affect the quality 
change. Further investigations should be performed to i entify other factors related to 
quality change which can help to improve the quality during the update process. 
 
4.3. Strengths and limitations 
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This study investigated the methodological and reporting quality of the 
non-Cochrane updated SRs and original SRs in both overall fully reported items and 
individual item of AMSTAR 2 and PRISMA checklists, which eliminates the question 
of potential differences in the weights of the items. Furthermore, we also conducted 
stratified analyses to examine certain characteristics that may affect the extent of the 
methodological and reporting quality changes during the update process. Findings 
from this study can be used to promote improvements in he quality and method of 
updated SR. However, our study has some limitations. First, the sample size included 
in this study is not large enough, although we searched two databases to incorporate 
all the eligible SRs and manually searched the reference lists of included SRs to 
obtain additional references. Since we were unable to identify all the SRs that did not 
explicitly state "update" in the titles or abstracts, many of them may have been 
ignored. Second, only SRs of RCTs published in English were enrolled, the results 
may not apply to SRs published in other languages and SRs of other types such as 
cohort studies and observational studies [22]. Third, the results of some stratified 
analyses on methodological quality and reporting quality may be less convincing 
because some subgroups contain only a small number of SRs. Fourth, since different 
teams may differ in the criteria for the assessment of AMSTAR 2 and PRISMA items, 
the credibility of the results of comparison with the quality of SRs in other areas may 
be weakened. Finally, we only used AMSTAR 2 and PRISMA assessed the 
methodological and reporting quality and did not evaluate the quality of Cochrane 
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systematic reviews. Further studies to explore the quality using other checklists and 
compare the quality of Cochrane reviews or reviews published in other databases 




The methodological and reporting quality of non-Cochrane updated SRs were 
not improved compared with the original SRs, although compliance rates were 
slightly improved on certain individual items. There is room for improvement of 
methodological and reporting quality for both original and updated SRs. The 
identified methodological and reporting deficiencies should be paid more attention, 
especially for the updated SRs. Future research should insistent on developing a 




SR: Systematic review; AMSTAR 2: Assessment of Multiple Systematic Reviews 2; 
PRISMA: Preferred Reporting Items of Systematic reviews and Meta-Analyses; RCT: 
randomized controlled trial. 
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Figure 1. The flowchart of the screening process. 
Figure 2. Compliance rate of updated SRs and originals SRs in each AMSTAR 2 item 
Figure 3. Comparison of the compliance rates of updated SRs and originals SRs in 
each AMSTAR 2 item. The X-axis represented each AMSTAR 2 item, the Y-axis 
represented the OR of updated SRs compared to original SRs, the bubble size 
displayed the number of OR, the color of the bubble indicated the OR is greater than 1, 
equal to 1, or less than 1. USRs, updated systematic reviews; OSRs, original 
systematic reviews; OR, odds ratio; AMSTAR 2, Assesment of Multiple Systematic 
Reviews 2. 
Figure 4. Compliance rate of updated SRs and originals SRs in each PRISMA item 
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Figure 5. Comparison of the compliance rates of updated SRs and originals SRs in 
each PRISMA item. The X-axis represented each PRISMA item, the Y-axis 
represented the OR of updated SRs compared to original SRs, the bubble size 
displayed the number of OR, the color of the bubble indicated the OR is greater than 1, 
equal to 1, or less than 1. USRs, updated systematic reviews; OSRs, original 
systematic reviews; OR, odds ratio; PRISMA, Preferrd Reporting Items for 
Systematic Reviews and Meta-analyses. 
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